194 related articles for article (PubMed ID: 1562720)
1. Varying intensity of postremission therapy in acute myeloid leukemia.
Cassileth PA; Lynch E; Hines JD; Oken MM; Mazza JJ; Bennett JM; McGlave PB; Edelstein M; Harrington DP; O'Connell MJ
Blood; 1992 Apr; 79(8):1924-30. PubMed ID: 1562720
[TBL] [Abstract][Full Text] [Related]
2. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
Cassileth PA; Andersen JW; Bennett JM; Harrington DP; Hines JD; Lazarus HM; Mazza JJ; McGlave PP; O'Connell MJ; Paietta E
Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
[TBL] [Abstract][Full Text] [Related]
3. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.
Reiffers J; Stoppa AM; Attal M; Michallet M; Marit G; Blaise D; Huguet F; Corront B; Cony-Makhoul P; Gastaut JA; Laurent G; Molina L; Broustet A; Maraninchi D; Pris J; Hollard D; Faberes C
Leukemia; 1996 Dec; 10(12):1874-82. PubMed ID: 8946925
[TBL] [Abstract][Full Text] [Related]
5. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
Jehn U
Leuk Lymphoma; 1994 Sep; 15(1-2):99-112. PubMed ID: 7532060
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
[TBL] [Abstract][Full Text] [Related]
8. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
10. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Harousseau JL; Cahn JY; Pignon B; Witz F; Milpied N; Delain M; Lioure B; Lamy T; Desablens B; Guilhot F; Caillot D; Abgrall JF; Francois S; Briere J; Guyotat D; Casassus P; Audhuy B; Tellier Z; Hurteloup P; Herve P
Blood; 1997 Oct; 90(8):2978-86. PubMed ID: 9376578
[TBL] [Abstract][Full Text] [Related]
11. Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
Wahlin A; Brinch L; Hörnsten P; Evensen SA; Oberg G; Simonsson B; Hedenus M
Eur J Haematol; 1997 Apr; 58(4):233-40. PubMed ID: 9186533
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy in childhood acute myeloid leukemia.
Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
[TBL] [Abstract][Full Text] [Related]
13. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
[TBL] [Abstract][Full Text] [Related]
15. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
[TBL] [Abstract][Full Text] [Related]
16. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Stevens RF; Hann IM; Wheatley K; Gray RG
Br J Haematol; 1998 Apr; 101(1):130-40. PubMed ID: 9576193
[TBL] [Abstract][Full Text] [Related]
17. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Kobayashi T; Miyawaki S; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Ohmoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Matsuoka A; Tomonaga M; Ohno R
J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
[TBL] [Abstract][Full Text] [Related]
18. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Zittoun R; Liso V; Mandelli F; Rotoli B; de Witte T; Gattringer C; Resegotti L; Caronia F; Leoni P; Petti MC
Leukemia; 1992; 6 Suppl 2():76-7. PubMed ID: 1578949
[No Abstract] [Full Text] [Related]
19. Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Harousseau JL; Milpied N; Briere J; Desablens B; Leprise PY; Ifrah N; Gandhour B; Casassus P
J Clin Oncol; 1991 Aug; 9(8):1432-7. PubMed ID: 2072146
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
